Aroa Biosurgery Limited (ASX:ARX)
0.5600
-0.0050 (-0.88%)
Aug 7, 2026, 4:13 PM AEST
Aroa Biosurgery Revenue
In the fiscal year ending March 31, 2026, Aroa Biosurgery had annual revenue of 103.85M NZD with 22.62% growth. Aroa Biosurgery had revenue of 58.99M in the half year ending March 31, 2026, with 58.61% growth.
Revenue
103.85M NZD
Revenue Growth
+22.62%
P/S Ratio
2.24
Revenue / Employee
944.13K NZD
Employees
110
Market Cap
193.71M AUD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 103.85M | 19.16M | 22.62% |
| Mar 31, 2025 | 84.70M | 15.63M | 22.63% |
| Mar 31, 2024 | 69.07M | 5.71M | 9.01% |
| Mar 31, 2023 | 63.36M | 23.68M | 59.68% |
| Mar 31, 2022 | 39.68M | 17.34M | 77.60% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PolyNovo | 139.49M |
| SomnoMed | 118.50M |
| Saluda Medical | 114.04M |
| Compumedics | 58.49M |
| Cyclopharm | 32.33M |
| Lumos Diagnostics Holdings | 18.31M |
| EBR Systems | 5.80M |
| EMVision Medical Devices | 5.43M |
Aroa Biosurgery News
- 2 months ago - Aroa Biosurgery Earnings Call Transcript: H2 2026 - Transcripts
- 2 months ago - Aroa Biosurgery Earnings release: H2 2026 - Filings
- 2 months ago - Aroa Biosurgery Slides: H2 2026 - Filings
- 2 months ago - Aroa Biosurgery Annual report: H2 2026 - Filings
- 6 months ago - Aroa Biosurgery Earnings Call Transcript: Q3 2026 - Transcripts
- 6 months ago - Aroa Biosurgery Earnings release: Q3 2026 - Filings
- 6 months ago - Aroa Biosurgery Slides: Q3 2026 - Filings
- 9 months ago - Aroa Biosurgery Earnings Call Transcript: H1 2026 - Transcripts